Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioequivalence revisited.

L B Sheiner1

  • 1Department of Laboratory Medicine, School of Medicine, University of California, San Francisco 94143-0626.

Statistics in Medicine
|September 30, 1992
PubMed
Summary
This summary is machine-generated.

New bioequivalence measures are proposed to better assess generic drugs, considering dose-response and clinical factors for patient safety. These measures address bias and variance in outcomes for both starting and switching drug regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamic measurements of methyl nicotinate percutaneous absorption.

Pharmaceutical research·2013
Same author

A new Bayesian method to forecast and fine tune individual hemodialysis dose.

Hemodialysis international. International Symposium on Home Hemodialysis·2009
Same author

Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Journal of pharmacokinetics and pharmacodynamics·2001
Same author

The need for mixed-effects modeling with population dichotomous data.

Journal of pharmacokinetics and pharmacodynamics·2001
Same author

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Journal of pharmacokinetics and pharmacodynamics·2001
Same author

Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2001
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Drug Regulatory Science
  • Biostatistics

Background:

  • Current FDA bioequivalence standards for generic drugs focus on population mean differences in bioavailability.
  • Existing methods may not fully account for dose-response relationships or critical clinical factors like starting or switching drug regimens.
  • The risk associated with bioinequivalence is not comprehensively modeled, particularly concerning outcome uncertainty.

Purpose of the Study:

  • To propose a comprehensive model for dose-response relationships in drug bioavailability.
  • To develop a tentative model for risk assessment in bioequivalence studies.
  • To introduce novel bioequivalence measures that integrate dose-response and risk considerations for different clinical scenarios.

Main Methods:

Related Experiment Videos

  • Development of a comprehensive dose-response model.
  • Formulation of a risk model addressing clinical circumstances and outcome uncertainty.
  • Proposal of two new bioequivalence measures derived from these models, accounting for bias and variance.

Main Results:

  • The proposed models provide a more nuanced approach to bioequivalence assessment.
  • The new measures are designed to differ based on whether a patient is initiating or switching a drug regimen.
  • Simulations and examples demonstrate the application and potential benefits of the proposed measures.

Conclusions:

  • The proposed bioequivalence measures offer a more clinically relevant and comprehensive assessment than current standards.
  • These measures better address the complexities of drug exposure, dose-response, and patient-specific risks.
  • The findings support a refined regulatory approach to generic drug approval, enhancing patient safety.